Roche Rules Out Merging R&D Units; Eyes Cuts in Sales

BASEL, Switzerland (Reuters) - Roche Holding AG (ROG.VX) is sticking to its dual-track research structure that some analysts have urged it to dismantle as the Swiss drugmaker seeks ways to slash costs after pipeline setbacks.